Skip to main content

Advertisement

Table 2 Median change of the Ki-67 labeling index and progesterone receptors

From: A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer

Variable Arm Baseline Surgery   
   Median IQR Median IQR Median change Contrast P
Ki-67 P 16 (9 to 22) 15 (10 to 23) 0 (-4 to 3) T vs. R P = 0.76
  T 18 (14 to 28) 19.5 (12.5 to 26.5) 0 (-5 to 4) T + R vs. P P = 0.78
  R 21.5 (15 to 27) 21 (15 to 25) 0 (-5 to 4)  
PgR P 80 (65 to 95) 90 (60 to 95) 0 (0 to10) T vs. R P = 0.10
  T 65 (10 to 90) 65 (22.5 to 92.5) 4.5 (-0.5 to 12.5) T + R vs. P P = 0.26
  R 80 (45 to 90) 70 (20 to 90) 0 (-5 to 5)  
ER P 90 (80 to 95) 90 (80 to 95) 0 (0 to 1) T vs. R P = 0.99
  T 90 (80 to 90) 90 (80 to 95) 1 (0 to 5) T + R vs. P P = 0.82
  R 90 (90 to 95) 90 (85 to 95) 0 (0 to 1)  
  1. IQR, interquartile range; P, placebo; T, tamoxifen 10 mg/week; R, raloxifene 60 mg/day; PgR, progesterone receptor; ER, estrogen receptor.